By Brian Hoyle
VIRTUAL -- May 5, 2021 -- Fluvoxamine may be repurposed to lessen the chance of clinical deterioration in outpatients with symptomatic coronavirus disease 2019 (COVID-19), according to a study presented at the Virtual 2021 Meeting of the American Psychiatric Association (APA).
“[The current] study reveals that patients treated with fluvoxamine, compared with placebo, had a lower likelihood of clinical deterioration over the course of 15 days,” stated Kishan Shah, MD, Rutgers New Jersey Medical School, Newark, New Jersey.
The fully remote contactless clinical trial compared fluvoxamine with placebo in regard to the clinical deterioration of outpatients who had not been hospitalised for treatment of confirmed COVID-19 infection. Between April 10, 2020, and August 5, 2020, 152 patients (109 women, 43 men; mean age, 46 years) were randomised to oral fluvoxamine 100 mg 3 times daily (n = 80) or placebo (n = 72) for 15 days.
The study took place between April 10, 2020 to August 5, 2020, with September 19, 2020 as the final follow-up date.
Clinical deterioration was defined as the development of symptoms, including shortness of breath or pneumonia, or hospitalisation for pneumonia and an oxygen saturation
None of the patients treated with fluvoxamine exhibited clinical deterioration, whereas 6 of the patients who received placebo showed clinical deterioration. The fluvoxamine group experienced 11 adverse events (AEs) and 1 serious AE. The placebo group reported 12 AEs and 6 serious AEs.
“The world is facing lockdown for the first time in decades due to the pandemic, leading to global disruption,” said Dr. Shah. “While we await widespread vaccination, these findings are encouraging, as fluvoxamine is widely available, affordable, and can be orally administered. Further exploration is likely to be met with great interest, as tools to prevent mild COVID-19 from progressing to severe disease are desperately needed.”
[Presentation title: Randomized Clinical Trial of Fluvoxamine Versus Placebo Shows Promise in Prevention of Clinical Deterioration in Outpatients With Symptomatic COVID-19]
To read more Conference Dispatch articles, click here.